Skip to main content
. Author manuscript; available in PMC: 2023 Feb 3.
Published in final edited form as: Hypertension. 2021 Apr 5;77(6):1990–2000. doi: 10.1161/HYPERTENSIONAHA.120.16870

Figure 4. AGT gene editing reduces blood pressure in hypertensive SHR.

Figure 4.

AAV8-Cas9 (control) or AAV8-Cas9-AGTgRNA (gene-editing) viral particles (2×1012 viral particles) were injected into the tail vein of adult (12-week old) female (top panels) and male (bottom panels) SHR with established hypertension. Blood pressure measurements were made by tail-cuff for up to 9 weeks post-injection. N=4–5 per group. ANOVA with Post-Hoc Bonferroni correction: Ns not significant, *P<0.05, **P<0.01, ***P<0.001. Individual data points are plotted. The mean of the control and gene-edited groups is shown by the solid and dashed line respectively. The curve was fitted as a polynomial of the 1st order.